BR0206495A - Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato - Google Patents

Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato

Info

Publication number
BR0206495A
BR0206495A BR0206495-2A BR0206495A BR0206495A BR 0206495 A BR0206495 A BR 0206495A BR 0206495 A BR0206495 A BR 0206495A BR 0206495 A BR0206495 A BR 0206495A
Authority
BR
Brazil
Prior art keywords
oxidase
antagonists
amino acid
treatment
dog
Prior art date
Application number
BR0206495-2A
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Original Assignee
Genset Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa filed Critical Genset Sa
Publication of BR0206495A publication Critical patent/BR0206495A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Abstract

"TRATAMENTO DE DISTúRBIOS DE CNS EMPREGANDO ANTAGONISTAS DE OXIDASE DE D-AMINOáCIDO E OXIDASE DE D-ASPARTATO". A presente invenção refere-se a compostos que são antagonistas de oxidase de D-aminoácido e oxidase de D-aspartato, métodos de tratar distúrbios de CNS incluindo distúrbio bipolar, psicose e esquizofrenia usando compostos, e composições farmaceuticamente aceitáveis que contêm os antagonistas.
BR0206495-2A 2001-01-16 2002-01-15 Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato BR0206495A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26188301P 2001-01-16 2001-01-16
US30544501P 2001-07-13 2001-07-13
US34521101P 2001-10-22 2001-10-22
US33388101P 2001-11-19 2001-11-19
PCT/IB2002/001262 WO2002066672A2 (en) 2001-01-16 2002-01-15 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists

Publications (1)

Publication Number Publication Date
BR0206495A true BR0206495A (pt) 2006-01-24

Family

ID=27500728

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206495-2A BR0206495A (pt) 2001-01-16 2002-01-15 Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato

Country Status (11)

Country Link
EP (1) EP1412515A2 (pt)
JP (1) JP2004537275A (pt)
KR (1) KR20030066813A (pt)
CN (1) CN1568370A (pt)
AU (1) AU2002247939B2 (pt)
BR (1) BR0206495A (pt)
CA (1) CA2433866A1 (pt)
EA (1) EA006654B1 (pt)
IL (1) IL156865A0 (pt)
MX (1) MXPA03006321A (pt)
WO (1) WO2002066672A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE408593T1 (de) 2001-05-03 2008-10-15 Galileo Lab Inc Pyruvatderivate
WO2003070743A1 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF G72 AND D-AMINO ACID OXIDASE (DAAO) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
US20030162825A1 (en) * 2001-11-09 2003-08-28 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
AU2002339696A1 (en) * 2001-12-03 2003-06-17 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
US20060234221A1 (en) * 2001-12-12 2006-10-19 Genset S.A. Biallelic markers of d-amino acid oxidase and uses thereof
GB0223424D0 (en) * 2002-10-09 2002-11-13 Imp College Innovations Ltd Disease-associated gene
CN1922149A (zh) 2003-12-29 2007-02-28 塞普拉科公司 吡咯和吡唑daao抑制剂
ATE500236T1 (de) * 2006-01-09 2011-03-15 Oklahoma Med Res Found Mit lanthionin verwandte verbindungen zur behandlung entzündlicher krankheiten
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
GB2456390A (en) * 2008-01-15 2009-07-22 Glaxo Group Ltd Bipolar disorder treatments
ES2615884T3 (es) 2009-01-20 2017-06-08 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Ácido sórbico y benzoico y sus derivados que aumentan la actividad de un neurofármaco
JP4462382B1 (ja) * 2009-04-23 2010-05-12 学校法人北里研究所 Ｄ−アスパラギン酸オキシダーゼおよびｄ−アミノ酸オキシダーゼに対する新規阻害剤
WO2012135119A1 (en) * 2011-03-25 2012-10-04 Genomind, Llc Biomarker-based detection and treatment of neurodegenerative depression
CA2866392C (en) 2012-03-30 2023-10-24 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
KR102403048B1 (ko) 2016-06-13 2022-05-26 신유알엑스 인터내셔널 (타이완) 코포레이션 벤조산나트륨의 공-결정 및 그의 용도
KR102488927B1 (ko) 2016-06-13 2023-01-13 신유알엑스 인터내셔널 (타이완) 코포레이션 벤조산리튬의 공-결정 및 그의 용도
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
CN108504752B (zh) * 2018-06-26 2021-05-11 华中农业大学 一种与母猪繁殖性状关联的分子标记及应用
CN111909907B (zh) * 2020-07-08 2022-05-24 浙江工业大学 天冬氨酸氧化酶突变体、工程菌及其在氧化-还原偶联制备精草铵膦中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
EP1165836A2 (en) * 1999-03-30 2002-01-02 Genset Schizophrenia associated genes, proteins and biallelic markers
AU6462500A (en) * 1999-07-29 2001-02-19 Patrick T. Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
US8030294B2 (en) * 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders

Also Published As

Publication number Publication date
WO2002066672A2 (en) 2002-08-29
AU2002247939B9 (en) 2002-09-04
KR20030066813A (ko) 2003-08-09
CA2433866A1 (en) 2002-08-29
MXPA03006321A (es) 2003-10-06
EA200300807A1 (ru) 2004-08-26
EA006654B1 (ru) 2006-02-24
IL156865A0 (en) 2004-02-08
WO2002066672A3 (en) 2004-02-26
AU2002247939B2 (en) 2007-01-25
JP2004537275A (ja) 2004-12-16
CN1568370A (zh) 2005-01-19
EP1412515A2 (en) 2004-04-28

Similar Documents

Publication Publication Date Title
BR0206495A (pt) Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
IL159418A0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EE200100485A (et) Uudsed ühendid ja kompositsioonid proteaasi inhibiitoritena
EA200401309A1 (ru) Тризамещённые гетероарилы и способы их получения и применения
NO20022655L (no) <Beta>-2-adrenerge reseptoragonister
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
BR0008056A (pt) Pirrolocarbazóis e isoindolonas cìclicas fundidas substituìdas
DK0842934T3 (da) 5-HT1F agonister
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
MA27412A1 (fr) Nouveaux pyrimidine-4,6-dicarboxamides pour l'inhibition selective de collagenases
EA200500173A1 (ru) Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
BR9912556A (pt) Triazolpiridinas para o tratamento de distúrbios trombóticos
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
NO20002408D0 (no) 5-HT1F antagonister
DE60302676D1 (de) Mucoadhäsive, wärmeaktivierbare Zubereitung als Träger für Medikamente
BR9807312A (pt) Derivados de (4-piperidinil)-1h-2-benzopirano úteis como agentes antipsicóticos
DK0804186T3 (da) Indolditerpenalkaloidforbindelser
BR0212451A (pt) Antagonistas de receptores de ccr-3 v
BR0317363A (pt) Antagonista de npy-5
CO5150221A1 (es) Nuevas 3-fenoxi- y 3-fenilalquiloxi-2-fenil-propilaminas sustituidas
FR2835253B1 (fr) Composes, en particulier de derives urees ou esters de l'acide haloacetamidobenzoique et leur utilisation pour le traitement de maladies parasitaires
BR0315046A (pt) Intermediários na preparação de aminoácidos bicìclicos fundidos terapêuticos
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.